News coverage about DURECT Corporation (NASDAQ:DRRX) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. DURECT Corporation earned a news impact score of 0.11 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 50 out of 100, meaning that recent news coverage is somewhat likely to have an effect on the company’s share price in the near future.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Brokerages Anticipate DURECT Corporation (NASDAQ:DRRX) Will Post Earnings of -$0.05 Per Share (americanbankingnews.com)
- Shedding Some Light on DURECT Corp (DRRX)’s Technicals – Sparta Review (spartareview.com)
- Short Interest in DURECT Corporation (NASDAQ:DRRX) Declines By 30.1% (americanbankingnews.com)
- Traders Sell Verizon Communications Inc. (VZ) on Strength on Insider Selling (badhub.net)
- Pulling the Curtain Back on DURECT Corp (DRRX) – Financial News Review (finnewsreview.com)
Shares of DURECT Corporation (NASDAQ:DRRX) opened at 1.76 on Friday. DURECT Corporation has a 52 week low of $0.74 and a 52 week high of $2.00. The firm’s market capitalization is $249.86 million. The firm’s 50-day moving average is $1.59 and its 200-day moving average is $1.18.
DURECT Corporation (NASDAQ:DRRX) last posted its quarterly earnings data on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.06). The firm had revenue of $4.57 million for the quarter, compared to analysts’ expectations of $3.60 million. DURECT Corporation had a negative return on equity of 318.49% and a negative net margin of 232.05%. Equities analysts anticipate that DURECT Corporation will post ($0.19) EPS for the current year.
Several brokerages have recently weighed in on DRRX. Stifel Nicolaus raised shares of DURECT Corporation from a “hold” rating to a “buy” rating and increased their price objective for the company from $1.25 to $3.00 in a research report on Wednesday, July 12th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of DURECT Corporation in a research report on Sunday, June 25th.
TRADEMARK VIOLATION WARNING: This article was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.chaffeybreeze.com/2017/07/30/somewhat-positive-media-coverage-somewhat-likely-to-impact-durect-corporation-drrx-share-price-updated-updated-updated.html.
About DURECT Corporation
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.